Abstract: A process for preparing complexes of piroxicam with cyclodextrins in which the two components in the powder state are premixed and then co-ground in a high energy mill in the presence of steam.The products obtained have technological, physical and biopharmacological characteristics which are advantageous compared with those of liquid-state complexes obtained by traditional methods, and are suitable for preparing pharmaceutical compositions for oral, rectal and topical use.

Abstract: 2-Propyl-2-pentanoic acid (valproic acid) esters and (E)-2-propyl-2-pentenoic acid [(E)-2-valproenoic acid] esters surprisingly proved to have valuable properties, in that they show anticonvulsive and antiepileptic activities comparable with those of valproic acid, as well as an improved bioavailability and a markedly reduced toxicity.

Abstract: 5,6-Dimethoxy-2-[2-(4-hydroxyphenyl)-2-hydroxy-2-methylethyl]amino- 1,2,3,4-tetrahydronaphthalene has inotropic and vasodilating activities and therefore can be used in the treatment of cardiocirculatory failure. The compound can be in the form of a single stereoisomer or as a mixture of two or more stereoisomers.

Abstract: The invention concerns an apparatus for the administration of drugs in form of metered aerosol, consisting of an expansion chamber comprising two coaxial tubes freely slidable within one another and detachable.The external tube has an open end and a tapered end on which the chamber month-piece is mounted.The internal tube has an open end which may be inserted into the external tube and on opposite end on which the month-piece of a conventional dispenser containing the active principle in form of pressurized aerosol is stuck.The apparatus allows a better penetration of the drug into the airways up to the deepest zones of the bronchial tree.

Abstract: Compounds of the formulaHet-S(O).sub.n -CH.sub.2 -A (I)wherein Het is a substituted imidazolyl, purinyl, thieno-imidazolyl or imidazo-pyridyl group, n is 0 or 1, A is one of the following structures: ##STR1## and their physiologically acceptable salts have antiulcer and gastric acid antisecretory activity.

Abstract: Imidazo[4,5-c] pyridine compounds and physiologically acceptable salts thereof having antiulcer and gastric acid antisecretory activities and pharmaceutical compositions containing them.

Abstract: Pharmaceutical compositions for the treatment of Parkinson's disease and neurologic syndromes connected with it, containing as the active principle levodopa methyl ester optionally combined with other active principles selected from dopaminergic, anticholinergic, antidepressive drugs, carboxylase and monoaminoxidase inhibitors.

Abstract: Isosorbide 2- and 5-mononitrate esters with aliphatic, aryl, or cynnamic acids or diacids, or with alkylcarbonyloxy substituents optionally containing an isosorbide 2- or 5-mononitrate group, are useful in human therapy.

Abstract: Aqueous pharmaceutical formulations containing the active principle piroxicam or N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxyamido-1,1-d iox ide, are described.The compositions of the invention are particularly suited for the injectable use, both because of their tolerability degree and for the favorable pharmacokinetics profile and may be advantageously used also for the preparation of collyria or eye-washes.

Abstract: Pharmaceutical compositions for the treatment of Parkinson's disease and neurologic syndromes connected with it, containing as the active principle Levodopa methyl ester optionally combined with other active principles selected from dopaminergi, anticholinergic, antidepressive drugs, carboxylase and monoaminoxidase inhibitors.

Abstract: The present invention relates to a process for the transformation of Piroxicam, N-(2-pyridyl)-2-methyl-4-hydroxy-2H-1, 2-benzothiazine-3-carboxamide 1,1-dioxide into an hydrated form, suitable for oral, topic or parenteral administration.

Abstract: Compounds of formula I ##STR1## wherein A represents: a saturated or unsaturated acyclic residue;a saturated cyclic or heterocyclic residue;a saturated or unsaturated bicyclic residue; and R represents OH, a C.sub.1 -C.sub.4 alkoxy group or a straight or heterocycle aminoresidue; R.sub.1 represents hydrogen, an alkyl group or an aromatic or heteroaromatic residue.Compounds I are endowed with valuable therapeutic characteristics.

Abstract: Compounds of formula I ##STR1## wherein A represents: a saturated cyclic or heterocyclic aromatic or heteroaromatic residue;a saturated or unsaturated bicyclic residue; and R represents H, an alkyl, cycloalkyl or alkoxyalkyl group.Compounds I are endowed with valuable therapeutic characteristics.

Abstract: New inclusion compounds of 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxyamide-1,1-dio xide with .alpha., .beta. or .gamma. cyclodextrins, obtained by reaction of said cyclodextrins and said 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxyamide-1,1-dio xide in aqueous or water/organic solutions are described. The ratio between 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-1,1-dioxide and the cyclodextrins is comprised between 1:10 and 1:1; preferably, it is about 1:2.5.The compounds of the invention possess high antiinflammatory and analgesic activities, together with a considerably reduced gastrolesive action.